Journal article
Incident cervical HPV infections in young women: Transition probabilities for CIN and infection clearance
RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, EA Joura, DG Ferris, M Steben, M Hernandez-Avila, DR Brown, E Elbasha, N Muñoz, J Paavonen, RM Haupt
Cancer Epidemiology Biomarkers and Prevention | Published : 2011
Abstract
Background: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions. Methods: Women ages 16 to 23 years underwent cytology and cervical swab PCR testing for HPV at approximately 6-month intervals for up to 4 years in the placebo arm of an HPV vaccine trial. The cumulative proportion of incident HPV infections with diagnosed CIN, clearing (infection undetectable), or persisting without CIN, were estimated. Results: Most incident infections cleared, without detection of CIN, ranging at 36 months from 66.9% for HPV31 to 91.1% for HPV59. There was little variation in the 36-month pro..
View full abstractGrants
Funding Acknowledgements
[ "G. Perez has received lecture fees and consultancy fees from Merck and Co., Inc. and Sanofi Pasteur MSD, and is now an employee of the sponsor, Merck and Co., Inc. C. M. Wheeler has received funding through her institution for reagents and equipment for Roche Molecular Systems in support of HPV genotyping studies and to conduct HPV vaccine studies for GlaxoSmithKline. D. G. Ferris has received consultancy, lecture, and advisory board fees from Merck and Co., Inc. and has received funding through his institution to conduct HPV studies for GlaxoSmithKline. S. M. Garland has received advisory board fees and grant support from Commonwealth Serum Laboratories and GlaxoSmithKline, lecture fees from Merck and Co., Inc., and research funds through her institution to conduct HPV vaccine studies for GlaxoSmithKline. S. M. Garland is a member of the Merck Global Advisory Board and the Merck Scientific Advisory Committee for HPV. S. Leodolter has received lecture fees from Merck and Sanofi Pasteur MSD. E. A. Joura has received advisory board fees from Merck and Sanofi Pasteur MSD, and has received funding through his institution to conduct epidemiological HPV studies for GlaxoSmithKline, and has received lecture fees from Merck and Co., Inc., Sanofi Pasteur MSD, and GlaxoSmithKline. D. R. Brown has received lecture fees, advisory board fees, and intellectual property fees from Merck and Co., Inc. M. Steben has received lecture fees and grant support from Merck and Co., Inc. M. Hernandez-Avila has received lecture fees and grant support from Merck and Co., Inc. J. Paavonen has received consultancy fees, advisory board fees, and lecture fees from Merck and Co., Inc. In addition, M. Hernandez-Avila, G. Perez, C. M. Wheeler, D. G. Ferris, L. A. Koutsky, S. M. Garland, S. Leodolter, E. A. Joura, M. Steben, D. R. Brown, and J. Paavonen have received funding through their institutions to conduct HPV vaccine studies for Merck. R. P. Insinga, E. Elbasha, and R. M. Haupt are employees of Merck and potentially own stock and/or stock options in the company. N. Munoz has received lecture fees and advisory board fees from Merck and Co., Inc. and Sanofi-Pasteur MSD.", "This study was supported by Merck Research Laboratories." ]